Harmony patents expiration
1. Wakix patents expiration
WAKIX's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7169928 | HARMONY | Non-imidazole alkylamines as histamine H3-receptor ligands and their therapeutic applications |
Feb, 2020
(4 years ago) | |
| US8207197 | HARMONY | Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy] propyl] -piperidine |
Mar, 2030
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7910605 | HARMONY | Non-imidazole alkylamines as histamine H3- receptor ligands and their therapeutic applications |
Sep, 2022
(1 year, 6 months ago) | |
| US8354430 | HARMONY | Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy]propyl]-piperidine |
Feb, 2026
(1 year, 9 months from now) | |
| US8486947 | HARMONY | Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands |
Sep, 2029
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 14, 2024 |
| Orphan Drug Exclusivity(ODE-255) | Aug 14, 2026 |
| Orphan Drug Exclusivity(ODE-331) | Oct 13, 2027 |
| New Indication(I-846) | Oct 13, 2023 |
Drugs and Companies using PITOLISANT HYDROCHLORIDE ingredient
NCE-1 date: 15 August, 2023
Market Authorisation Date: 14 August, 2019
Treatment: Method of treating cataplexy in patients with narcolepsy
Dosage: TABLET;ORAL
More Information on Dosage
WAKIX family patents
